Bouziani Myriam, Kraaijeveld Rens, Junger Henrik, Rejas Carolina, Siska Peter J, Schuster Antonia, Amann Kerstin, Daniel Christoph, Ferrazzi Fulvia, Feldker Nora, Hinze Christian, Jahn Lorenz, Huyan Yige, Schödel Johannes, Hesselink Dennis A, Banas Bernhard, Baan Carla C, Steines Louisa
{"title":"Targeted inhibition of Bcl6 effectively suppresses alloactivation of CD4<sup>+</sup> T cells with potential for T cell-directed immunosuppression.","authors":"Bouziani Myriam, Kraaijeveld Rens, Junger Henrik, Rejas Carolina, Siska Peter J, Schuster Antonia, Amann Kerstin, Daniel Christoph, Ferrazzi Fulvia, Feldker Nora, Hinze Christian, Jahn Lorenz, Huyan Yige, Schödel Johannes, Hesselink Dennis A, Banas Bernhard, Baan Carla C, Steines Louisa","doi":"10.1016/j.ajt.2026.11.005","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.11.005","url":null,"abstract":"<p><p>Bcl6 is a key transcriptional repressor regulating T cell fate; however, its role in T cell alloimmune responses is largely unknown. We investigated Bcl6 expression in T cells within allografts and the potential of targeting Bcl6 to modulate CD4<sup>+</sup> T cell alloactivation. Using mIFISH, we found that Bcl6<sup>+</sup>CD4<sup>+</sup> T cells were highly prevalent in kidney transplant biopsies during rejection. In mixed lymphocyte reactions, pharmacological Bcl6 inhibition (Bcl6i) potently suppressed proliferation and effector cytokine production of human CD4<sup>+</sup> T cells in a dose-dependent manner. Acting in PBMC and isolated T cell subsets alike, Bcl6i effects were direct, T cell-specific and irrespective of T cell differentiation state. Gene expression and flow cytometry showed Bcl6i reshaped T cell fate by altering key transcriptional programs. Bcl6i suppressed Th1, Th2 and Th17 transcription factors and upregulated TCF1. In addition, T cell inhibitory receptor TIGIT was up- and costimulatory receptor ICOS downregulated. Importantly, we validated the response to Bcl6i in donor-reactive CD4<sup>+</sup> T cells from kidney transplant patients, highlighting the translational potential of Bcl6 as a target for T cell-directed immunosuppression in transplantation.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Risk Assessment for Transmission of Porcine Endogenous Retrovirus in Clinical Xenotransplantation.","authors":"Jay A Fishman, Larisa Rudenko, David H Sachs","doi":"10.1016/j.ajt.2026.11.002","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.11.002","url":null,"abstract":"<p><p>Porcine to human xenotransplantation clinical trials are underway. Concerns remain regarding potential transmission of infections including porcine endogenous retroviruses (PERVs) to human xenotransplant recipients with adverse health outcomes. All pigs contain subtypes PERV-A and PERV-B, and some also carry PERV-C. Human cells carry receptors for PERV-A and -B but not for PERV-C. PERV-A can recombine with PERV-B to form PERV-A/B hybrids and recombine with PERV-C to form PERV-A/C hybrids in vivo and in vitro. No evidence of PERV transmission to non-human primates or other laboratory animals, human primary cells, or to humans from surgical or non-surgical exposures has been reported, although transmission of PERV A/C hybrids has been observed in certain permissive transformed human cell lines. PERV inactivation has been achieved via genetic editing in some pig lines. Here, we review the data related to the potential for PERV infection in human xenograft recipients based on published data on PERV structure and host cellular and species tropisms. Despite the lack of evidence regarding transmissibility of PERVs to humans, we advocate the rigorous monitoring of patients and, possibly, their close contacts in initial clinical trials for possible PERV transmission following xenotransplantation.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149400353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Catherine R Butler, Léa Pessin, Richard K Blankenhorn, Evan P Carey, Hannah Eyre, David K Prince, Peter P Reese, Ann M O'Hare
{"title":"Varied trajectories through the transplant evaluation process: Results of a sequence analysis among a national cohort of Veterans with advanced kidney disease.","authors":"Catherine R Butler, Léa Pessin, Richard K Blankenhorn, Evan P Carey, Hannah Eyre, David K Prince, Peter P Reese, Ann M O'Hare","doi":"10.1016/j.ajt.2026.11.001","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.11.001","url":null,"abstract":"<p><p>Efforts to improve access to kidney transplant are limited by an incomplete view on the full arc of the evaluation process. We performed a retrospective cohort study among 39,691 adults receiving care within the US Veterans Affairs Health Care System (VA) with incident advanced kidney disease (eGFR≤20 mL/min/1.73 m<sup>2</sup>) between 10/1/2011 and 12/31/2018. We used sequence analysis to describe sequential steps in the transplant process over 5 years of follow-up. Cohort members' median age at cohort entry was 70.1 (IQR 63.9, 80.2) years and 97.2% were men. Sequence analysis yielded 7 distinct trajectories through the transplant process: 1) early death (50.5%), 2) transplant not mentioned (24.6%), 3) not pursuing transplant (6.2%), 4) prolonged deliberation (4.6%), 5) prolonged evaluation (8.9%), 6) timely waitlisting (3.3%), and 7) timely transplant (1.9%). Older age, higher comorbidity index, and higher area deprivation index were associated with a lower likelihood of experiencing trajectories representing timely progression through the transplant process and a greater likelihood of not engaging with the process or spending prolonged periods of time in early steps. Our findings suggest that current efforts to encourage broader referral for transplant should be complemented by a more streamlined evaluation process and support for shared decision-making.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CD8 T cell phenotype diagnoses graft-versus-host disease after liver transplantation.","authors":"Shifei Song, Wei Qiu, Yuguo Chen, Qing Yang, Ziqi Huang, Wenchao Zhao, Xiaodong Du, Guangzhao Shao, Youxi Yu, Peitong Li, Xiaoliang Liu, Yunyi Li, Xuxiang Xia, Daqun Liu, Jiaao Yu, Xiaodong Sun, Ying Yu, Alfred Kow Wei Chieh, Shuhong Yi, Yang Yang, Mingqian Li, Guoyue Lv","doi":"10.1016/j.ajt.2026.10.030","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.10.030","url":null,"abstract":"<p><p>Graft-versus-host disease (GVHD) is a rare but highly fatal complication following liver transplantation (LT). While donor T cell chimerism is a specific diagnostic indicator, its detection via short tandem repeat (STR) analysis is compromised in LT-GVHD. Here, peripheral blood from nine patients diagnosed with LT-GVHD by STR chimerism or histopathology was analyzed using HLA-specific antibody-based flow cytometry for simultaneous donor T cell chimerism and immunophenotyping. Flow cytometry detected macrochimerism in all patients, including three with negative leukocyte STR results. All patients exhibited lymphocytopenia, with the three cases specifically exhibiting significantly elevated granulocyte-to-lymphocyte ratios, suggesting donor DNA dilution by recipient granulocytes underlies STR false-negatives. Donor-derived CD8<sup>+</sup> T cells were predominant and exhibited a TEM-biased phenotype with heightened proliferation, activation, exhaustion, and cytotoxicity compared to GVHD recipient-derived T cells or non-GVHD donor-derived T cells. This immunophenotypic signature was readily detectable within the total CD8<sup>+</sup> TEM population, allowing Ki-67-based diagnosis without requiring HLA-specific antibodies. Its diagnostic relevance was further confirmed in an independent external cohort. We conclude that lymphocyte enrichment is essential for reliable STR-based chimerism detection in LT-GVHD. HLA-specific flow cytometry or Ki-67 assessment on total CD8<sup>+</sup> TEM cells offers a practical alternative tailored to the lymphopenia context of LT-GVHD.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149392213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"CD154 Blockade Improves Polyfunctionality of T Cells Specific for a Murine Homolog of Epstein-Barr Virus.","authors":"Katie L Alexander, Mandy L Ford","doi":"10.1016/j.ajt.2026.11.003","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.11.003","url":null,"abstract":"<p><p>Anti-CD154 is a promising therapeutic for solid organ transplantation with ongoing clinical trials, but its impact on the immune response to EBV is unknown. Here, B6 animals were infected with a murine homolog of EBV (MHV68) and treated with anti-CD154 costimulation blockade. Results indicate that the ratio of virus-specific CD8<sup>+</sup> T cells to MHV68-infected cells was not significantly reduced following in vivo anti-CD154. Interestingly, frequencies of multi-cytokine producing CD4<sup>+</sup> and CD8<sup>+</sup> T cells were increased following treatment with anti-CD154 compared to either CTLA4-Ig or tacrolimus. This increased polyfunctionality was mechanistically underpinned by an increase in the frequency of CD8<sup>+</sup> T cells expressing the memory/stem-like transcription factors TCF-1 and Eomes in the anti-CD154 group compared to CTLA-4Ig, tacrolimus, or untreated controls. Moreover, anti-CD154-treated mice exhibited smaller spleens with a significant decrease in the number of MHV68-YFP<sup>+</sup> germinal center B cells compared to untreated mice. These data demonstrate that CD154 blockade does not significantly decrease the ratio of virus-specific T cells to infected cells and increases the quality of MHV68-specific CD8<sup>+</sup> T cells in a mouse model. Overall, these findings suggest that an anti-CD154 costimulation blockade-based immunosuppression regimen may be beneficial regarding its ability to preserve protective anti-viral immunity during transplantation.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149384801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Combined Rituximab and Daratumumab Induces Remission in Refractory Post-Transplant Crescentic IgA Nephropathy.","authors":"Xuchao Zhang, Chunchun Wei, Gui Zheng, Dicui Yao, Meifang Wang, Qin Zhou, Rending Wang, Jianghua Chen, Wei Hu, Jianyong Wu, Yu Cui","doi":"10.1016/j.ajt.2026.10.031","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.10.031","url":null,"abstract":"<p><p>Recurrent crescentic IgA nephropathy (IgAN) after kidney transplantation is rare, aggressive, and often refractory to standard immunosuppression. We report a 17-year-old recipient with biopsy-confirmed recurrent crescentic IgAN two years after transplantation despite corticosteroids and targeted-release budesonide. Rescue therapy comprised one rituximab infusion with daratumumab, followed by four daratumumab infusions. Proteinuria decreased from 5.21 to 0.06 g/g, serum albumin normalized, and allograft function remained stable through day 482 after the first rescue infusion. Longitudinal CyTOF and flow cytometry showed sustained peripheral B-cell depletion and transient NK-cell reductions. One mild upper respiratory infection occurred. Sequential biopsies showed resolution of the active cellular crescent, although mesangial IgA staining and electron-dense deposits persisted. These clinical, histologic, and immune changes were temporally associated with combined CD20- and CD38-targeted therapy. This single case cannot establish efficacy, distinguish the contributions of rituximab and daratumumab, or exclude effects of preceding and supportive treatments, but supports further study of this rescue approach.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
E Hendren, J Lan, M Kadatz, V Sridhar, G Avgay, D O'Donoghue, V Farkas, J Borg, W Rojas, J S Gill
{"title":"Induction immunosuppression in kidney transplant recipients treated with early corticosteroid cessation: A propensity score case-matched analysis.","authors":"E Hendren, J Lan, M Kadatz, V Sridhar, G Avgay, D O'Donoghue, V Farkas, J Borg, W Rojas, J S Gill","doi":"10.1016/j.ajt.2026.10.029","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.10.029","url":null,"abstract":"<p><p>Early corticosteroid cessation is recommended for low immune risk kidney transplant recipients, but the optimal induction immunosuppression is uncertain. We compared the outcomes of 4,770 first kidney only transplant recipients in the U.S. between 2010 and 2022 treated with tacrolimus and mycophenolate without corticosteroids induced with interleukin-2 receptor antagonists (IL-2Ra) to a matched cohort induced with anti-thymocyte globulin rabbit ( Thymoglobulin.) Only 13% of patients treated with early corticosteroid cessation were induced with IL-2Ra and these patients were more likely to be older and have diabetes. After 1:1 matching, patients treated with IL-2Ra had a higher adjusted risk of allograft loss from any cause (Hazard Ratio (HR) = 1.20, 95% confidence interval (CI) 1.12 to 1.29), death with allograft function (HR = 1.20, 95% CI 1.10 to 1.31), and allograft loss with death as a competing risk (sub hazard ratio SHR = 1.20, 95% CI 1.04 to 1.38). We conclude that IL-2RA induction is selectively used in older, sicker patients but is associated with a higher risk of transplant failure compared to matched patients treated with Thymoglobulin. The findings highlight the need for prospective trials to define optimal induction in patients who may benefit most for early corticosteroid cessation.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Rhiannon D Reed, Ruiqi Xue, Alvin G Thomas, Jasmine Akhtar, Gayathri Menon, Samantha Weiss, Dorry L Segev, Darren E Stewart, Babak J Orandi, Nicole M Ali, Jeffrey M Stern, Allan B Massie, Macey L Levan
{"title":"Landscape Of Post-Donation Follow-up of Living Kidney Donors in the United States, 2013-2023.","authors":"Rhiannon D Reed, Ruiqi Xue, Alvin G Thomas, Jasmine Akhtar, Gayathri Menon, Samantha Weiss, Dorry L Segev, Darren E Stewart, Babak J Orandi, Nicole M Ali, Jeffrey M Stern, Allan B Massie, Macey L Levan","doi":"10.1016/j.ajt.2026.10.027","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.10.027","url":null,"abstract":"<p><p>Post-donation follow-up is critical for living kidney donor (LKD) care, facilitating early detection of unusual decrease in renal function and providing opportunities for early intervention. Herein, we update and characterize temporal trends in LKD follow-up (LDF) using Organ Procurement and Transplantation Network data. We identified 64,488 LKDs (2/2013-12/2023) and used logistic regression to assess donor characteristics associated with complete and timely (defined per current OPTN policy) LDF at 6-months, 1-year and 2-years post-donation. The proportion of complete and timely LDF submissions was generally consistent since 2013 for clinical and laboratory data at each time point. Overall, complete and timely 6-month, 1-year, and 2-year LDF were 84%, 81% and 75% for clinical data, and 80%, 75% and 68% for laboratory data. Across all time points, LKDs with pre-donation BMI≥30, Black race, and of younger age had higher odds of incomplete follow-up. We also observed substantial center-level variation, with the proportion of transplant centers meeting 6-month LDF thresholds ranging from 56-81% each year. In this retrospective registry analysis, LDF remained suboptimal and varied by center and donor characteristics, demonstrating the need for targeted approaches to improve LDF, particularly among those at increased risk of kidney disease or facing barriers to care.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hillary Akana, Kaitlin Logue, Brenden R O'Neale, Kimberly Elliott, Sara O Dionne
{"title":"Reevaluation of the role of HBsAg testing in deceased tissue and cornea donor eligibility determination.","authors":"Hillary Akana, Kaitlin Logue, Brenden R O'Neale, Kimberly Elliott, Sara O Dionne","doi":"10.1016/j.ajt.2026.10.028","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.10.028","url":null,"abstract":"<p><p>The utility of hepatitis B surface antigen (HBsAg) testing in deceased tissue and cornea donor eligibility screening is uncertain in the era of concurrent hepatitis B virus (HBV) nucleic acid testing (NAT) and hepatitis B core total antibody (anti-HBc) screening. We performed an analysis of 300,112 deceased tissue and cornea donors. screened for eligibility between January 2021 and May 2026. Donors were screened for HBV NAT, HBsAg, and anti-HBc; results were analyzed to characterize HBV screening profiles and evaluate the incremental yield of HBsAg reactivity among donors with nonreactive NAT results. Overall, 97.02% of donors (n=291,180) had HBsAg-nonreactive/HBV NAT-nonreactive results and 0.11% (n=318) of donors had HBsAg-reactive/HBV NAT-reactive results. In 0.57% of donors (n=1,697) HBsAg-nonreactive/HBV NAT-reactive results were obtained and 2.30% of donors (n=6,917) were HBsAg-reactive/HBV NAT-nonreactive. Among HBsAg-reactive/HBV NAT-nonreactive donors, 97.79% (n=6,764) were also anti-HBc-nonreactive. HBsAg testing identified 22.5 additional reactive screening results (per 1,000 donors) among donors without HBV NAT and anti-HBc reactivity. A subset of reactive HBsAg specimens were evaluated by supplemental confirmatory testing (n=1,131); only 17.28% were confirmed reactive. In this cohort, HBsAg testing identified potential donors for whom the biological significance of HBsAg reactivity remains uncertain, and current eligibility requirements result in donor exclusion.</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Joshua A Jacobs, Spencer J Carter, Miklos Z Molnar, Konstantinos Sideris, Dominik Jenca, Ersilia M DeFilippis, Kiran K Khush, Roberta Florido, Jan Benes, Aditya Mehta, Stavros G Drakos, Stephanie Davis, Amanda Sarpolis, Craig H Selzman, Matthew L Goodwin, Hiroshi Kagawa, Alison M Brann, Thomas C Hanff, Eleni Tseliou, James C Fang, Maryjane Farr, Josef Stehlik
{"title":"Impact of the Safety-Net Kidney-After-Heart Transplant Policy on Simultaneous Heart-Kidney Transplant Volume and Outcomes in the United States.","authors":"Joshua A Jacobs, Spencer J Carter, Miklos Z Molnar, Konstantinos Sideris, Dominik Jenca, Ersilia M DeFilippis, Kiran K Khush, Roberta Florido, Jan Benes, Aditya Mehta, Stavros G Drakos, Stephanie Davis, Amanda Sarpolis, Craig H Selzman, Matthew L Goodwin, Hiroshi Kagawa, Alison M Brann, Thomas C Hanff, Eleni Tseliou, James C Fang, Maryjane Farr, Josef Stehlik","doi":"10.1016/j.ajt.2026.10.021","DOIUrl":"https://doi.org/10.1016/j.ajt.2026.10.021","url":null,"abstract":"<p><p>On 6/29/2023, the Organ Procurement and Transplantation Network (OPTN) implemented a safety-net policy providing priority kidney transplant (KT) listing status to heart transplant (HT) recipients who develop persistent kidney dysfunction within one year of HT, with the intent of incentivizing isolated HT over simultaneous heart-kidney transplantation (sHKT) in patients with potentially reversible kidney dysfunction. The impact of this policy on sHKT utilization and post-transplant outcomes is unknown. We used interrupted time series analysis of quarterly sHKT volume and compared one-year mortality and kidney graft failure between pre- and post-policy sHKT recipients using multivariable Cox models. In this OPTN registry analysis of HTs performed from 1/1/2020-12/31/2025, among 21,688 HT recipients, 1,133 pre-policy and 877 post-policy recipients underwent sHKT, and 183 received a safety-net KT. We found that 1) following policy implementation, the quarterly change in slope of sHKT utilization was -4.45 procedures per quarter (95% CI -5.94, -2.95), with a concurrent rise in safety-net KT of 2.52 per quarter (95% CI 1.44, 3.59), 2) mortality and kidney graft failure were similar among sHKT recipients post- vs pre-policy implementation (hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.68, 1.29 and HR 0.91, 95% CI 0.67, 1.24, respectively).</p>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.1,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149376376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}